Back to User profile » Dr Yayi He
Papers published by Dr Yayi He:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy
Zhang H, Zhao W, Li X, He Y
OncoTargets and Therapy 2021, 14:3803-3812
Published Date: 21 June 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
Wang H, Chen S, Meng D, Wu C, Zhu J, Jiang M, Ning J, Wu S, Wu L, Li J, Chen B, Zhao S, Li W, Yu J, Fang Q, Zhu J, Zhao W, He Y, Zhou C
OncoTargets and Therapy 2021, 14:2953-2965
Published Date: 4 May 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research
Wang H, Meng D, Guo H, Sun C, Chen P, Jiang M, Xu Y, Yu J, Fang Q, Zhu J, Zhao W, Wu S, Zhao S, Li W, Chen B, Wang L, He Y
OncoTargets and Therapy 2021, 14:1895-1909
Published Date: 16 March 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
Sun C, Zhang L, Zhang W, Liu Y, Chen B, Zhao S, Li W, Wang L, Ye L, Jia K, Wang H, Wu C, He Y, Zhou C
OncoTargets and Therapy 2020, 13:6475-6483
Published Date: 3 July 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review
Chen S, He Y, Liu J, Chen X, Yu J, Li W, Chen B, Sun C, Zhou C
OncoTargets and Therapy 2019, 12:11305-11311
Published Date: 19 December 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Comparison of Double Sleeve Lobectomy by Uniportal Video-Assisted Thoracic Surgery (VATS) and Thoracotomy for NSCLC Treatment
Wu L, Wang H, Cai H, Fan J, Jiang G, He Y, Jiang L
Cancer Management and Research 2019, 11:10167-10174
Published Date: 2 December 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
Yi C, He Y, Xia H, Zhang H, Zhang P
OncoTargets and Therapy 2019, 12:7329-7336
Published Date: 6 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C, He Y
OncoTargets and Therapy 2019, 12:7347-7353
Published Date: 6 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment
Wang H, Zhao S, Zhang X, Jia K, Deng J, Zhou C, He Y
OncoTargets and Therapy 2019, 12:7281-7288
Published Date: 5 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
TIM-3, a promising target for cancer immunotherapy
He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR
OncoTargets and Therapy 2018, 11:7005-7009
Published Date: 16 October 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
sLAG-3 in non-small-cell lung cancer patients’ serum
He Y, Wang Y, Zhao S, Zhao C, Zhou C, Hirsch FR
OncoTargets and Therapy 2018, 11:4781-4784
Published Date: 13 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
He YY, Liu ST, Mattei J, Bunn Jr PA, Zhou CC, Chan D
Drug Design, Development and Therapy 2018, 12:981-986
Published Date: 24 April 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules
He Y, Yang Y, Kuang P, Ren S, Rozeboom L, Rivard CJ, Li X, Zhou C, Hirsch FR
OncoTargets and Therapy 2017, 10:5915-5926
Published Date: 13 December 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
He YY, Sun WW, Wang Y, Ren SX, Li XF, Li JY, Rivard CJ, Zhou CC, Hirsch FR
OncoTargets and Therapy 2016, 9:2409-2414
Published Date: 21 April 2016